Latest Breaking News On - Frank neumann - Page 1 : comparemela.com

Achertäler Druckerei wins three Finat Label Awards 2024

Achertäler Druckerei wins three Finat Label Awards 2024
labelsandlabeling.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from labelsandlabeling.com Daily Mail and Mail on Sunday newspapers.

Baden wübergBastian fialaWaldulmer winzergenossenschaftFrank neumannFelix neumannGroup winner of printingPinot noirFinat label awardsGroup winnerPrinting processes

Orna Therapeutics Appoints Frank Neumann, M D , Ph D , as Chief Medical Officer

Orna Therapeutics Appoints Frank Neumann, M D , Ph D , as Chief Medical Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNordrhein westfalenTom barnesFrank neumannAnsbert gadickeHead of oncology clinical researchGlobal head of clinical developmentGilead companyUniversity of texas md anderson cancer centerTakeda pharmaceuticalsVerastem incHeinrich heine universityRheinische friedrich wilhelm universityIndustry leader brings decadesStrategic clinicalCell therapy expertise

Yescarta Label Updated With Overall Survival Data in Large B-Cell Lymphoma

The prescribing information for Yescarta® (axicabtagene ciloleucel) has been updated to include OS data in adults with relapsed or refractory LBCL.

Frank neumannGlobal head of clinical developmentSenior vice presidentGlobal headClinical development

FDA Updates Label for Axicabtagene Ciloleucel for R/R LBCL Following Positive Long-Term Survival Data

The CAR T-cell therapy improved relative overall survival by more than a third compared to standard of care.

Frank neumann

FDA Approves Label Updates to Include New Data for Axi-Cel in LBCL, Zanubrutinib in CLL

The FDA has approved label updates for zanubrutinib to include data from the ALPINE trial in relapsed/refractory chronic lymphocytic leukemia, and axicabtagene ciloleucel to include findings from the primary overall survival analysis of the ZUMA-7 trial in relapsed/refractory large B-cell lymphoma.

Mehrdad mobasherFrank neumannClinical development at kiteClinical developmentLabel updates for zanubrutinibAlpine trialPatients with relapsed refractory chronic lymphocytic leukemiaAxicabtagene ciloleucelZuma 7 trialPatients with relapsed refractory largeb cell lymphoma